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A BST R A C T

Cardiovascular disease, including hypertension, accounts for almost 50% of the deaths in
patients with end stage renal disease (ESRD) on hemodialysis (HD) yet hypertension
remains very poorly controlled in this population. The purpose of this study was to
retrospectively compare control of hypertension in hemodialysis (HD) patients when
extracellular volume (ECV) was assessed and managed by clinical parameters and
physical assessment data alone with control of hypertension when data from blood
volume monitoring (BVM) technology was also used to assess and manage ECV in a
freestanding outpatient hemodialysis unit. The main cause of hypertension in the ESRD
population has been identified as increased ECV most likely secondary to increased
interdialytic weight gain and failure to attain and maintain patient’s dry weight. HD
nurses often employ clinical parameters along with physical examination to determine a
patient’s pre, intra, and post dialytic fluid status and this approach can have a high index
of error. BVM technology is being used in many hemodialysis units to assist with
assessment of ECV. A comparative retrospective chart review was used to collect data for
this project. A descriptive, cross-sectional design was employed to answer the
question:“Are hypertensive hemodialysis patients who dialyze in a freestanding dialysis
unit, where BVM technology is utilized, more likely to be normotensive as defined by a
pre dialysis blood pressure of less than 140/90 and post dialysis blood pressure less than
130/80”? A pilot study was conducted to determine if the patient population and data
were available in existing patient records for extrapolation. Approval for the study was
obtained from the University IRB. A convenience sample was obtained from the records
of patients meeting the inclusion criteria. Variables were measured and analyzed using
iii

descriptive statistics such as sampled paired T-test to compare pre and post BVM
systolic, diastolic blood pressures, intradialytic weight gain, serum Albumin and sodium
levels, and hemoglobin. A p-value of 0.05 was assigned for statistical significance. Data
analysis showed there were statisticaly significant differences in the pre dialysis systolic
blood pressure, post BVM, and the serum sodium pre and post BVM when the two
groups were compared These statistically significant findings support a correlation
between reduction in the HD patient’s ECV and improved blood pressure control. The
reduction of pre-dialysis SBP was significant because many patients on hemodialysis
have systolic hypertension that may or may not coexist with diastolic hypertension. The
findings of this study may be used to formulate a protocol to be used in the HD units
where the BVM is available. The protocol would rely on accurate nursing assessment of
clinical parameters, patient verbalizations of symptoms, and the routine use of the BVM
in order to continuously assess the patient’s fluid status. Future research
recommendations include conducting the study in a population closer to the national
sample, a study where glucose readings and /or hemoglobin A1C levels are measured to
assess the impact of glucose on ECV, and which antihypertensive class of medication
works best with BVM technology to effectively manage hypertension in this population.
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C H A PT E R 1: I N T R O D U C T I O N

O utline for T hesis
This chapter will discuss the current assessment models and management of HTN
and ECV in the HD patient. The purpose of Chapter 2 is to present the research reports
and evidence based recommendations. Chapter 3 will describe the design and
implementation of the project. Chapter 4 will present and discuss the results and Chapter
5 will present conclusions and suggestions for future studies.

Problem/Significance
According to the United States Renal Data System (USRDS; National Institute of
Diabetes and Digestive and Kidney Diseases [NIDDKD], 2008) there were 360,000
ESRD patients in the U.S. of which 93% receive hemodialysis and 7% receive peritoneal
dialysis (PD). Hypertension (HTN) is the second leading cause of chronic kidney disease
(CKD) and ESRD (NIDDKD, 2008) yet HTN remains widely uncontrolled even once the
patient makes the transition to ESRD (Aggarwal, 2003). It is estimated that 87% of
diabetic HD patients and 67% of non-diabetic HD patients have inadequate blood
pressure control (Mailloux, 2001). Hypertension is the leading and undisputed leading
cause of cardiovascular disease (CVD; Zoccali, Mallamaci, & Tripepi, 2000). In the
ESRD population, CVD is the predominant cause of morbidity and mortality.
The mortality rate for dialysis patients in the United States is 20 % approximately
50% of which is from CVD (Hlebovy, 2006) The most common cause of hospital
admissions for HD patients is CVD related diagnoses. CVD related diagnoses account for
49% of chronic and 40% of acute admissions of that pulmonary edema being the most
1

common admitting diagnosis (Hlebovy, 2006). The use of antihypertensive medications
is not as effective in CKD Stage 5 and ESRD because the cause hypertension in this
population is most likely camouflaged volume retention (Hlebovy, 2006). The use of
Thiazide and Loop diuretics in late stages of CKD and ESRD has a diminished effect
secondary to the severely decreased glomelular filtration rate (GFR) and potassium
sparring diuretics are contraindicated due to the increased risk of hyperkalemia (Izzo,
Sica, & Black, 2008).
The pathophysiological cause of HTN in ESRD, after secondary causes have been
ruled out, is extracellular volume (ECV) expansion (Hlebovy, 2006). Total body water is
contained within 2 compartments: intracellular (within the cells) and extracellular
(outside the cells). The intracellular compartment holds about 60% of total body water
and the ECV holds about 40% of which 20% is within the plasma volume (Mitchell,
2002). ECV is the fluid contained in the interstitial, transcellular, and the intravascular
spaces (Mitchell, 2002).
As renal failure worsens, the ability of the kidneys to balance sodium and water
output dramatically decreases leading to sodium and water excess that may abet HTN by
expanding the ECV and increasing ventricular wall stress (cardiac output) during systolic
ejection. The foundations of managing HTN in HD patients are achieving appropriate dry
body weight through dialysis, interdialytic fluid restriction, attending HD sessions,
adhering to prescribed dietary guidelines and medication therapy (Denhaerynck et al.,
2007).
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Background of H ypertension in H D Patients
Hypertension is estimated to be present in up to 80% of ESRD patients sometimes
as the primary cause of renal failure but more often as a secondary complication ESRD
where inaccurate patient assessment of ECV status or patient complications during HD
(i.e. hypotensive episodes) leads to decreased fluid removal (Savage, Fabbian, Gibbs,
Tomson, & Raine 1997). The result of decreased fluid removal is increased ECV which
may lead to hypertension. Hlebovy (2006) concluded that 90% of HD patients could
become normotensive by lowering the ECV and focusing on the patient’s dry weight.
Assessment of the patient’s fluid status is based on the patient’s dry weight (DW).
DW, as it pertains to the ESRD population, is defined as the lowest weight a patient can
tolerate without the development of symptoms (i.e. cramping) or hypotension in the
absence of antihypertensive medications (Rodriguez, Domenici, Diroll and Goykhman,
2005). Appropriate DW is directly correlated with control of blood pressure and notably
increased HD patient survival rates (Hlebovy, 2006).
In many dialysis units, DW is assessed by the presence or absence of clinical
parameters and physical exam such as dyspnea, headache, periorbital and pre-tibial
edema, postural dizziness, cramps, hypotension and hypertension. Raimann, Lui, Ulloa,
Kotanko, and Levin (2008) found that none of these clinical parameters and physical
findings were sufficiently specific or sensitive to DW and fluid assessment and may
exhibit a large margin of error due to patient variability.
The problem with DW assessment based on purely clinical grounds is that dry
weight cannot be assessed by a single parameter (Locatelli et al., 2004). Factors such as
the patient’s residual renal function as evidenced by urinary output, other sources of fluid
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loss such as diarrhea and emesis, and interdialytic well being such as appetite and energy
levels, should be incorporated and reassessed at least every 2 weeks to assure the
patient’s post dialysis weight reflects an accurate DW and management of ECV
(Locatelli et al., 2004). Jaeger and Mehta (1999) studied the current methods of ECV/DW
assessment method of dry weight and concluded that it was difficult to determine whether
a patient was over-hydrated or under-hydrated even when these assessment methods are
properly employed.
Four emerging technological methods that show promise are being used and have
gained popularity in recent years within the HD community. These methods include the
use of biochemical markers, vena cava diameter, bioimpedence, and blood volume
monitoring (BVM). Of the 4 methods discussed, BVM, which has been available since
1992, has become the most widely used and accepted method of assisting in the
determination of a patient’s ECV fluid status in both in- and outpatient settings
(Rodriguez, Domenici, Diroll and Goykhman, 2005).
BVM determines ideal body weight non-invasively by directly measuring the
change in blood volume by monitoring the fluid volume and oxygenation in the intravascular space. BVM monitors the patient’s real time hematocrit because red blood cells
(RBC) are too large to pass through the dialyzer. RBC mass remains constant during the
dialysis treatment (Donauer, 2004) but hematocrit levels have an inverse relationship
with hydration status within the human body. An increased hematocrit, per BVM, is
highly representative of reduction of the ECV and the decreased hematocrit represents
increased in ECV (Donauer, 2004).
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The BVM displays a picture of the patient’s volume status based on the variability
of the patient’s real time hematocrit and Oxygen levels. The clinician is able to adjust the
DW and rate of fluid removal by monitoring the patient and BVM every 15 minutes. The
BVM has the ability to notify the clinician of impending intradialytic complications such
as hypotension and cramping by displaying changes in the patient’s hematocrit and
oxygenation levels for which the clinician has been trained to observe and intervene
appropriately (Donauer, 2004).
Many dialysis personnel involved in the assessment of the patient’s BP and fluid
status rely on the patient’s past post dialysis weights, complaints, or lack of complaints of
symptoms such as muscular cramping, post HD fatigue, and pre-dialysis blood pressure
to determine the patient’s target fluid removal. Some clinics use BVM along with clinical
parameters and physical exam to assist in determining the patient’s ECV status. The an
education of Nephrology nurses and ancillary staff such as certified dialysis technicians
on the clinically significant link between HTN and ECV status may lead to an improved
knowledge base and eventually improved overall outcomes.

H ypertension in H D Patients: T he Nursing Community T akes A ction
The reported prevalence of HTN in HD patients is estimated to be between 50%90% (Purcell, Williams, & Walker, 2004). Antihypertensive medications do not reduce
the blood pressure effectively in this population because the most likely etiology of HTN
in HD patients is increased ECV. Therefore The American Nephrology Nurses
Association (ANNA) viewed fluid management as an area of concern and convened a
special interest group (SIG) in 2004. The goal of the SIG was “to supply information
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about accurate dry weight measurement and the effects of inaccurate measurement “ to
the nephrology nursing community.
The objectives of the SIG included reviewing the long-term complications of
hemodialysis related to fluid volume excess and fluid volume deficit and to assess the
effectiveness of the BVM as a tool to assist in obtaining the ideal DW. The SIG
concurred BVM would be helpful in managing ECV but stated more studies were needed
(Purcell, Williams, & Walker, 2004). CVD is the leading cause of morbidity and
mortality in the HD patient. Long term HTN not only affects the patient’s morbidity and
mortality but also the patient and their families/ loved ones quality of life. Another issue
is that long term HTN may hinder the patient’s chances of possible kidney (living or
cadaver) transplant as the heart of a patient with uncontrolled HTN may be enlarged and
have left ventricular hypertrophy which may hinder cardiac output and may not have
enough cardiac output to sustain the needed blood flow to the transplanted kidney.
Nephrology practitioners now have 4 decades of clinical and physical assessment
knowledge and, in some facilities, the assistance of technology to manage fluid volume
and HTN. Improving BP control in this vulnerable population is a collaborative effort
among the nursing, medical, dietary, and social work providers involved in the patient’s
care. The ANNA SIG on fluid management position statement announced it is time for
nephrology nurses and the nephrology industry to accept accountability and include fluid
management (clinical parameters, physical exam and available tools such as BVM) as
part of the HD standards of care which may be located within the National Kidney
Foundation’s Kidney Dialysis Outcomes Quality Initiatives (NKF-KDOQI) guidelines
(2006).
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The SIG continued by stating the goal of fluid management should be in line with
dialysis pioneers such as Dr. Scribner’s who defined DW as the post dialysis weight that
allows the BP to remain normal (less than 130/80 mm/hg) until the next dialysis session,
without the use of antihypertensives, and despite interdialytic weight gain (NKF-KDOQI,
2006). In 1961 Dr. Belman Scribner, the father of chronic dialysis, made the observation
HTN may be controlled by low sodium diet and fluid removal during HD (Shaldon,
2002). The first patients were dialyzed for 6-8 hours three times a week. The long
dialysis sessions allowed for the removal of increased fluid volume and toxin removal. In
the first 3 out of 4 long-term HD patients treated by Dr. Scribner, anti-hypertensive
medications were stopped secondary to hypotensive episodes (Shaldon, 2002).

O bjectives/A ims
This review of the current state of science revealed the potential benefit of
managing HTN in the HD patient by assessing the ECV status and attaining euvlomemia
using clinical parameters and BVM technology as an adjunctive tool. Effective HTN and
fluid circumspection is directly related to decreased CVD associated morbidity and
mortality. The NKF-KDOQI guidelines regarding the management of HTN in HD
patients emphasize attention to the patient’s fluid status (Clinical Practice Guidelines,
2006). Kidney Disease: Improving Global Outcomes (KDIGO), the international
consortium HTN management guidelines recommend gradual reduction of the patient’s
DW as antihypertensive medications are withdrawn. Therefore, HTN management in the
HD patient through approximating the ECV status is recommended by both the KDOQI
and KDIGO guidelines in attempt to decrease CVD associated morbidity and mortality.
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1. Provide data to support the use of tools such as the BVM will effectively manage
the ECV thereby assist in control of hypertension in HD patients.
2. Improving the patient and/or their families/loved ones quality of life by
decreasing CVD associated morbidity and mortality by effectively controlling
ECV status.
This study aims to answer the question “Are HD patients who dialyze in a
freestanding HD unit where BVM technology is used as an adjunctive tool along with
assessment of clinical parameters more likely to be normotensive (BP < 140/90 predialysis. 130/80 post-dialysis) secondary to achieving and maintaining an adequate dry
weight?” The feasible, interesting, novel, ethical, and relevant (FINER) criteria was used
to determine the research question. The author deems the project to be feasible based on
the availability and appropriateness of records on which to evaluate the impact of the use
of the BVM in addition to clinical parameters The completed project will contribute to
the literature, which supports the belief that HTN may be managed in HD patients with
appraisal of clinical parameters and fluid management utilizing BVM technology. This
project is ethical as the researcher adhered to the ethical principles of respect for persons,
beneficence, and justice as outlined in the Belmont Report. Lastly, the relevance of this
project has been attested by previous studies and reports that document that a large
percentage of HTN is HD patients secondary to excess ECV status.

V ariables
The patient records reviewed were records of hypertensive HD patients in which
secondary causes of HTN have been excluded and reflected use of BVM within the past
12 months. The records were reviewed to obtain pre and post dialysis weights, blood
8

pressure measurements, albumin, hemoglobin and sodium levels. The identified variables
were pre and post intervention systolic and diastolic blood pressure, interdialytic weight
gains, albumin, hemoglobin and sodium measurements. The variables were statistically
analyzed to reveal relationships, where and if available. The data collection tool was
developed to obtain the necessary data from the patient’s record to meet the project’s
objectives and complete statistical analysis to positively or negatively answer the
research question. The research question stated: Are HD patients who dialyze in a
freestanding HD unit where BVM technology is available and used as an adjunctive tool
along with assessment of clinical parameters more likely to be normotensive (BP <
140/90 pre-dialysis. 130/80 post-dialysis) by attaining and maintaining a euvolemic state?

Definition of Terms
1. Antihypertensive medications: Medications prescribed by the patient’s provider(s)
to control hypertension. Medications must be current and information will be
collected on the data collection tool according to classification. Categories
include: ACE-I, ARB, beta-blocker, calcium channel Blocker, central adrenergic
blockers, alpha blockers, alpha-beta blockers, vasodilators, diuretics
2. Clinical parameters: Assessment of weight, blood pressure, presence or absence
of fluid deficit or excess before and after dialysis
3. Co-morbidities: Any chronic illness that may affect the patient and their quality of
life. This information taken from the 2728 form.
4. Euvolemia The state of fluid equilibrium. The fluid state at which there are no
signs of extracellular fluid deficit (hypovolemia) or extracellular fluid excess
(hypervolemia).
9

5. Hypertension (HTN) in hemodialysis (HD) patients: Pre-dialysis blood pressure
(BP) greater than 140/90 mm/hg and post-dialysis BP greater than 130/80 mm/hg.
6. Increased IDWG: Greater than 3000 ml gained in between prescribed dialysis
sessions.
7. Interdialytic weight gain (IDWG): Weight change calculated by subtracting post
weight from pre-dialysis weight. Was measured in ml
8. Prescribed treatment time: Time prescribed to be spent on dialysis, measured in
minutes, prescribed by the provider to ensure dialysis adequacy and safe fluid
removal.
9. Primary cause of renal failure: The cause of decreased renal function necessitating
the initiation of dialysis. This data will be taken from the 2728 form (see
Appendix A), which is a standardized form every patient is required to have as
part of his or her chart.
10. Sodium profile: HD machine setting that allows for an increase amount of sodium
to be delivered through the dialysate:


Hemoglobin 10-12 mg/dl



Serum albumin 3.5-5.0



Serum glucose 60-100 mg/dl



Serum sodium: 135-145 mEq/L.

11. Ultrafiltration (UF) profile: HD machine setting that allows for fluid removal at
different rates.
The primary cause of end stage renal disease was obtained from the patient’s
2728 form (see Appendix A). The Centers for Medicare and Medicaid Services (CMS)
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requires the form for all newly diagnosed ESRD patients, regardless of their Medicare
status or treatment modality. The 2728 form serves two purposes. The purposes are to
provide medical evidence of an end-stage renal condition for Medicare entitlement, and
to register the patient in a national renal registry. CMS provides the data to the USRDS
for public reference and use in research. The patient’s co-morbidities was obtained from
the 2728 and listed on the data collection tool (see Appendix B).

Assumptions


There will be adequate patient population meeting inclusion criteria.



The recorded data will be accurate and reliable.



Correct analysis of data to answer the research question

Importance of Proposed Project
The proposed project will help fill gaps in nursing/medical knowledge regarding
HTN and management of ECV in the hypertensive HD patient by promoting the need for
ongoing ECV status and adjustment of DW. The obtained knowledge will contribute to
nursing/medical knowledge by dispelling myths and supporting facts about that
effectively managing the ECV status to improve control of HTN and may lead to the
discontinuation of antihypertensive medication in some patients. The conducted research
sought to lead to the implementation of best clinical practices in addition to KDOQI and
KDIGO guidelines.
Benefits of standardization would include an improvement in the clinical staff’s
ability to assess a patient’s volemic state and improve the chances of achieving and
maintaining the DW without experiences complications such as inter and intradialytic
11

hypotension, cramps, nausea and/or vomiting, The study’s results may positively impact
the practice of healthcare providers by assisting them to help meet the conditions of
coverage (COC) as defined by CMS. The COC state “the principal goal of these
conditions is to improve cardiovascular outcomes by optimizing fluid management
practices and strategies during hemodialysis” (Hlebovy, 2008, p. 442). The conditions
may be met by decreasing or preventing hospitalizations, decreasing morbidity and
mortality rates associated with cardiac events by astute assessment and maintenance of
the patient’s fluid status. Patient benefits include improved quality of life as evidenced by
reduction in left ventricular mass that has been shown to decrease incidences of
arrthymias and sudden cardiac death. The benefit of increased quality of life and patient
longevity are priceless.
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C H A PT E R 2: L I T E R A T U R E R E V I E W

Pu rpose
The purpose of this literature review is to consider the discussions and data
surrounding assessing extracellular volume (ECV) volume in hypertensive HD patients.
The literature and guidelines reviewed indicate that HTN in the ESRD population is
largely attributed to increase ECV and HTN, which remains uncontrolled despite accurate
nursing assessment and provider intervention. The expected increase in the number of
patients dependent on HD, along with economic impact of providing competent care, has
increased the need to control HTN in this population.

Background
Investigators have concluded that cardiovascular disease (CVD) is the leading
cause of morbidity and mortality in the ESRD population (Locatelli et al., 2004). The
distinguishing CVD risk factors in the ESRD populations are: volume overload with
consequent hypertension, anemia, deranged calcium-phosphorus metabolism,
accumulation of specific uremic toxins, and chronic inflammatory processes (Locatelli et
al, 2004). Unresolved hypertension contributes to the increased workload of the heart by
affecting preload and afterload. Purcell, Manias, Williams, and Walker (2004) concluded
hypertension particularly increases afterload.
The main etiology of HTN in the ESRD population is ECV expansion (Purcell,
Manias, Williams, and Walker, 2004). Guyton et al. established the significant role the
kidneys play in the homeostasis of sodium and ECV (Purcell, Manias, Williams, and
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Walker, 2004). An individual with normal kidney function balances salt and water intake
through the gut and salt and water output through the kidneys that ultimately maintains
the size of the ECV (Charra, 2007).
As renal failure worsens the ability of the kidneys to excrete sodium decreases
thereby leading to sodium excess that may abet HTN by expanding the ECV and
increasing ventricular wall stress (cardiac output) during systolic ejection. This
ventricular wall stress is known as afterload (Purcell, Manias, Williams, and Walker,
2004)
Afterload refers to factors that augment ventricular wall stress during systolic
ejection (Purcell, Manias, Williams, and Walker, 2004). Sustained hypertension increases
afterload and may result in left ventricular hypertrophy (LVH; 2004). LVH increases
oxygen demands of the myocardium leading to increased risk of ischemic heart disease
and possibly fatal arrhythmias. Foley et al. (1996) authenticated a lineal relationship
between longstanding hypertension and the development of LVH. Horl and Horl (2002)
established that LVH is a common characteristic of patients with kidney failure and
significantly reduces their life expectancy. Foley (1996) documented that for every
10mm/hg increase in mean arterial pressure (MAP) there was a 48% increased risk of
LVH. The state of euvolemia is known as achieving a patient’s dry weight (DW). The
definition of a patient’s dry weight was formulated based on multiple ideations but best
stated by Charra (2007) as the lowest weight a patient can tolerate without intra and
interdialytic symptoms such as hypotension and with no to minimal antihypertensive
agents. Assessment of DW in HD patients relies heavily on clinical parameters (i.e. vital
signs, patient comments, and physical exam). This imprecise method fails to take into
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account the dynamic nature of DW. DW may change during any period of illness,
wellness, depression, gain and loss of lean body weight that may affect DW (Purcell,
Manias, Williams, and Walker, 2004).
The pillar of managing uncontrolled HTN in HD patients, after secondary causes
have been eliminated, is achieving appropriate DW. Secondary causes of HTN in dialysis
patients include activation of sympathetic nervous system, increased blood viscosity,
stimulation of the Renin-Angiotensin system, and electrolyte shifts (Stankus, 2010). The
problem of assessing dry weight on purely clinical grounds is rooted in the fact dry
weight cannot be assessed by a single parameter (Purcell, Manias, Williams, and Walker,
2004). Providers in the HD unit estimate DW. Factors such as the patient’s interdialytic
well being, including appetite and energy level, should be incorporated and reassessed at
least every 2 weeks to assure the patient’s post dialysis weight reflects an accurate DW
(Purcell, Manias, Williams, and Walker, 2004).
Hypertension is the leading and undisputed leading cause of CVD (Zoccali,
Mallamaci, & Tripepi, 2002). In the ESRD population CVD mortality is the predominant
cause of death. The USRDS annual report (NIDDKD, 2008) noted approximately 45% of
overall mortality in ESRD patients receiving HD are attributed to cardiac events. The
NKF-KDOQI guidelines state the HD prescription should be individualized to help the
patient achieve euvolemic and normotensive states utilizing fluid control (2006). The
need to provide clinicians with improved assessment skills in the field of ECV
assessment is imperative to improve patient outcomes, patient quality of life, and
decreased morbidity and mortality associated with uncontrolled HTN secondary to ECV
excess.

15

Blood Pressu re G uidelines in H emodialysis Patients
The NKF-KDQOI were first published in 2002, and revised in 2006, provide the
framework for the treatment of uncontrolled hypertension in the ESRD patient. The NKF
KDQOI guidelines are categorized into blood pressure management and management of
hypertension (NKF-KDQOI, 2006). Blood pressure management in the ESRD patient is
based on pre-dialysis blood pressure to guide antihypertensive therapy since blood
pressure varies significantly upon the timing of the measurement.
These guidelines state that it is difficult to relate usual BP readings to the ESRD
patient because studies have shown both pre and post dialysis readings to measure 14
points higher systolically and 5 points diastolically as compared to the non-ESRD patient
(NKF-KDQOI, 2006). The guidelines also cite the availability of enough current data to
define optimal blood pressure in ESRD patients so the committee selected 140/90 mm/hg
as a pre-dialysis blood pressure target and 130/80 mm/hg as a post dialysis target.
The guidelines clearly support the benefit of a lower target blood pressure but cite
the increased morbidity and mortality of lower blood pressures in the ESRD population.
This may be explained by reverse epidemiology according to Borsboom et al. (2006).
The investigators found that long term uncontrolled hypertension coupled with increased
ECV led to LVH, systolic, and diastolic dysfunction. The ESRD patient with severe
cardiac failure presents as hypotensive in spite of their fluid status. The ESRD patient
with this severe form of cardiac failure has a 1.5-3 times higher probability of death in
the next 3-7 years as compared to the hypertensive ESRD patient (Borsboom et al, 2006).
The NKF-KDQOI guidelines (2006) also cite dietary and nutritional management
recommendations of HTN in the HD patient. The first recommendation states the
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patient’s dietary sodium intake should be limited to 80 to 100 mEq/d. Tomson (2001)
suggested that the nephrology community should concentrate on advising and helping
dialysis patients to limit their salt intake which will help limit their thirst. Tomson
continued by stating that patients drink for one of two reasons: thirst and because they
feel like a drink (2001). Therefore, asking a patient to adhere to a fluid restriction without
a sodium restriction is useless because if a patient’s sodium intake exceeds their output
the stimulus to drink will be present due the body’s drive to maintain serum osmolarity
(2001).
In 2008 the Department of Health and Human Services, Centers for Medicare and
Medicaid (CMS) published new guidelines for condition of coverage (COC) for
establishing minimum health and safety standards for improving care and protecting
Medicare and Medicaid beneficiaries (CMS, 2008). The conditions of coverage state “the
adverse effects of ESRD, many patients experience labiality of blood pressure and fluid
management, the management of which may require reassessment of medication needs,
adjustments in target weight, and changes to the plan of care. The comprehensive
assessment should include evaluation of the patient’s pre/intra/post and interdialytic
blood pressures, interdialytic weight gains, target weight, and related intradialytic
symptoms (e.g., hypertension, hypotension, muscular cramping) along with an analysis
for potential root causes”. Both in and out patient dialysis facilities must meet the
standards in order to be paid by CMS and since CMS is the major payer for those
receiving HD. (CMS, 2008). Under the conditions of coverage an interdisciplinary team,
consisting of the patient, registered nurse, physician, advanced practitioner, social
worker, and dietician, are to convene to develop an appropriate plan of care.
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Therefore, successful blood pressure and fluid management is mandated in order
for dialysis units, physicians, and allied health professionals to be reimbursed (CMS,
2008).
Assessment of volume status in the HD patient involves the multi-disciplinary
team approach of HD nurses, dieticians, patients and their caregivers. Although ECV
assessment is not a precise science the perceptive HD nurse may employ various
assessment methods including clinical parameters, physical exam, and in certain cases
technology to assist in ECV management.

Assessment of Volume Status
Dry weight (DW), as it pertains to the ESRD population, is defined as the lowest
weight a patient can tolerate without the development of symptoms (i.e. cramping) or
hypotension in the absence of antihypertensive medications (Charra, 2007). In many
dialysis units around the world DW is assessed by the presence or absence of symptoms
such as dyspnea, headache, periorbital and pre-tibial edema, postural dizziness, cramps,
hypotension and hypertension. Raimann, Lui, Ulloa, Kotanko, and Levin (2008) found
that none of these symptoms were sufficiently specific or sensitive and exhibit a large
inter and intra-individual variability. The earliest finding of fluid overload is jugular vein
distention (JVD) and it is rarely assessed in dialysis units (Raimann, Lui, Ulloa, Kotanko,
and Levin, 2008).
Historically, assessment of volume status in the hypertensive HD patient has been
elicited by measurement of clinical parameters and physical exam pre, intra, and post
HD. Jaegar and Mehta (1999) found clinical assessment of ECV is crude and imprecise
due to overestimation and underestimation of DW. Overestimation of DW leads to HTN,
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cerebral vascular accidents (CVA), and congestive heart failure (CHF) that have been
identified as the leading causes of death in the HD patient (Jaegar and Mehta, 1999).
Underestimation of DW frequently leads to persistent hypotensive episodes, which may
cause patient alienation from their HD caregivers by affecting delivery of dialysis
through decreasing or missing HD sessions.
Mitchell concluded (2002) pre-dialysis clinical assessment of ECV and DW is
highly dependent on vital signs such as blood pressure, heart rate, temperature and in the
case of HD patients their pre-dialysis weight. Pre-dialysis HTN may be secondary to
excessive intra-dialytic weight gain (>3 kgs) (Reams and Elder, 2003). Reams and Elder
also stressed the importance of assessing pre-dialysis HTN was not secondary to missed
or held anti-hypertensive therapy. The importance of accurate pre-dialysis weight
measurement should never be underestimated (Mitchell, 2002). Charra (2007) concluded,
based on his clinical studies, that errors in weighing are frequent and may adversely
impact the dialysis tolerance and the estimation of DW. Simple measures should be
employed such as ensuring the scale is calibrated to zero pre and post treatment and
educating the patient to wear similar clothing to every HD session to maintain pre-HD
weight consistency.
One of the most important pre-dialysis clinical assessment tools is determining
the patient’s residual renal volume. The residual renal volume is the amount of
interdialytic urine volume along with extrarenal water losses such as diarrhea, vomitus,
and nasogastric secretions (Pace, 2007). Pace, concluded, a HD patient’s fluid allowance
is 600 ml additional per 24 hours in addition to the patient’s urine output and extrarenal
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water losses. Consistent assessment of a HD patient’s fluid allowance is paramount in
preventing overestimation and underestimation of the patient’s volume status.
Pre-dialytic and intra-dialytic volume assessment continues with physical exam
and eliciting patient comments regarding interdialytic and intradialytic quality of life and
general wellbeing (Mitchell, 2002). Purcell, Manias, Williams, and Walker (2004) found
that the patient in the HD unit who attracts the most attention by experiencing
hypotensive episodes, nausea and vomiting, or cramping during or after their dialysis
treatment are more likely to report a perceived decrease in their quality of life. Intradialytic patient complaints of fatigue, edema, or dyspnea that may lead to the inability of
the patient to carry out activities of daily living are vital to astute volume assessment. The
clinician should also refer to treatment history, preferably 2 weeks’ worth of treatment
data, to assist in determination of volume status (Mitchell, 2002).
The patient’s post dialysis weight coupled with the presence or absence of
orthostatic hypotension may lead the HD nurse towards determining whether the DW is
accurate or in need of adjustment. Charra (2007) found predialysis, interdialysis, and post
dialysis assessment of edema often points to ECV excess but HD nurses must also assess
the patient’s cardiac function and serum albumin.
HD patients are often malnourished and a low albumin level leads to leakage of
intravascular fluid into interstitial spaces, which leads to visible edema (Mitchell, 2002).
Agarwal, Andersen, and Pratt (2008) undertook a study to answer the question “What is
the role of pedal edema in the HD patient”? The cross-sectional study of asymptomatic
HD patients’ deduced assessment of volume state is an important component of day-today treatment of HD patients. The study concluded lower extremity edema correlates
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with cardiovascular risk factors such as age, body mass index, and left ventricular mass
but does not reflect volume in HD patients. Clinical parameters such as vital signs,
patient’s complaints, and physical exam are critical components to assessment of ECV
status but nursing knowledge is crucial in executing efficient and effective patient
outcomes. Coupled with the need for keen nursing assessment is the advent of technology
to assist with ECV management.

Blood Volume Monitoring
Assessment of ECV in HD has long depended on edema, presence or absence of
dyspnea, HTN, fatigue and patient complaints. This imprecise method fails to take into
account the dynamic nature of DW in which any period of illness, depression, gain or
loss of lean body weight may affect ECV (Purcell, Manias, Williams, and Walker 2004).
Of all the advancements in dialysis therapy the use of the blood volume monitor (BVM)
has proven to be the most useful tool in DW attainment with little risk of hypotensive
episodes in the ESRD patient (Heerspink et al., 2009). BVM is a non-invasive method,
which monitors the fluid available in the intravascular space against the rate of fluid
removal during dialysis.
This is accomplished by measuring plasma refill during the hemodialysis process.
Plasma refill is the shift of poisons and fluids from the intracellular space to the
extracellular space into the intravascular space/circulating blood volume. During the
dialysis session, excess fluids and toxins are removed from the circulating blood volume
and if there is excess fluid or toxins in either the intracellular or extracellular
compartments it is shifted to the intravascular space. This process is known as plasma
refill (Heerspink et al, 2009).
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The BVM utilizes the patient’s hematocrit (HCT) increased or decreased ECV has
a direct inverse relationship with a increase or decrease blood volume measured through
real time HCT (Leypoldt et al., 2002). Steuer, Germain, Leypoldt, and Cheung (1998)
concluded that the use of BVM during HD facilitated the identification of patients with
increased ECV while permitting greater removal of excess body fluids without a
substantial increase symptom during treatment.
BVM allows the HD nurse to utilize clinical parameters and physical exam to
predict and avoid interdialytic morbidity such as hypotensive episodes. Charra (2007)
concluded BVM in conjunction with discerning nursing judgment might result in
decreased patient morbidity and mortality. BVM is particularly useful when assessing
ECV status in hypertensive elder patients that have decreased body water related to
increased body fat, decreased muscle mass and decreased ability to regulate water and
sodium balance (McCance & Huether, 1998).
The advantages of the BVM are that HD nurses and staff are able to make
immediate changes to the rate and volume of fluid removal before an adverse patient
event. The disadvantages of BVM use are lack of access to the majority of HD patients
secondary to economic factors and accurate interpretation of the data by nursing staff.
Purcell, Manias, Williams, and Walker (2004) looked at whether clinical parameters and
physical exam used alone or in conjunction with BVM yielded improved outcomes. They
found the most important component is seasoned nursing judgment.
The autonomy of the dialysis nurse is well known within the health care
community. Dialysis nurses autonomy may be secondary to the highly technical nature of
their practice and the need to make immediate decisions regarding the patient’s treatment
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often without the presence of a physician or advanced practitioner. Bonner and Walker
(2004) examined nephrology nurses and their role in the blurring of boundaries as it
relates to patient care. The study’s participants included 6 novice nephrology nurses and
11 expert nephrology nurses. This study utilized a grounded theory methodology and
symbolic interaction. Nephrology nurses, in particular HD nurses, are known for their
autonomy.
Nurses’ autonomy in dialysis units stem from the highly specified nursing tasks
that untrained and novice nurses, physicians and ancillary staff are unable to perform. In
order for a nurse to be considered safe and competent, an average of at least 12-18
months training is needed (Bonner and Walker, 2004). Expert nephrology nurses were
defined as nurses with more than 5 years hemodialysis experience and novice nurses
were defined as nurses with less than 5 years experience. Although Nephrologists and
advanced practice practitioners are competent in managing HD patients, many lack the
knowledge and technical ability to perform the actual treatment and its associated
functions.
The study found that only the expert nephrology nurses were more likely to make
patient care decisions that would normally involve a provider’s order and did so by
moving intermittently and purposefully for the benefit of particular patients. Expert
nurses, in this study, altered medications that were used to treat symptoms of renal failure
such as electrolyte imbalances, anemia, and hypertension. The nurse’s actions consisted
mainly of reducing or stopping a drug and adjusting fluid removal during HD. The study
highlighted the fact that nephrology nurses tend to act in the immediate interest of patient
by stabilizing a potentially dangerous situation. Educating the staff regarding what
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benefits the patient in the long run will influence current treatment decisions and
outcomes (Bonner and Walker, 2004) by setting protocols that will allow all nurses to
practice within their scope.

Summa ry
The goal of this literature review was to assess the current literature and
guidelines as related to assessment of ECV status in uncontrolled HTN in HD patients.
The purpose of this literature review is to support the assessment of ECV status through
clinical parameters and physical assessment and where available BVM. The findings of a
project directed at determining whether there is improved patient outcomes when clinical
parameters and physical exam is used compared to clinical parameters, physical exam,
and BVM may lead to the purchase and use of the BVM in settings where it is currently
not available.
The NKF-KDOQI guidelines state the HD prescription should be individualized
to help the patient achieve euvolemic and normotensive states utilizing fluid and sodium
control (National Kidney Foundation’s Executive Summary, 2006). The need to provide
clinicians with improved assessment skills and protocols in the area of ECV assessment
are imperative to improve patient outcomes, and decrease morbidity and mortality
associated with CVD. DW assessment and determination is well within the scope of
practice of HD nurses. Attempts to improve ECV volume status assessment will increase
patient’s quality of life as well as decreasing costs associated with medications and
hospitalizations.
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C H A PT E R 3: M E T H O D O L O G Y

A retrospective, descriptive, cross-sectional design was employed in the chart
review process. The identified population consisted of patients of a freestanding
hemodialysis unit in the Southern-Eastern United States with the diagnosis of ESRD and
HTN with secondary causes of HTN excluded. A data collection instrument was used to
obtain needed data. The descriptive design was chosen because it allowed the researcher
to observe, chronicle, archive facets of HTN and ECV assessment and management in the
HD patient. The patient records were available to the researcher during the operating
hours of a facility that employs BVM as a fluid management tool.
The makers of the BVM, HemaMetric, state the monitor is a continuous quality
improvement management tool that allows clinicians to safely and consistently dialyze
patients to their ideal DW, resulting in improved measurable patient outcomes such as
decreased fluid related hospitalizations, decreased pre-dialysis HTN, and decreased
number of antihypertensive medications.
The use of descriptive research in this study provided insight into the validity of
the BVM maker’s claims as well as making observations based on trends among the
hypertensive HD patients whose records were reviewed. Descriptive research allows the
researcher to explore exposed relationships among the variables even in the presence of
large amounts of collected data. An identified advantage of appropriating descriptive
research is that the what, when, where, and why of the research question is answered.
Disadvantages of the descriptive research method are that the information gathered may
be ubiquitous and risk for potential research bias is possible.

25

Sampling
The size of the study’s sample was determined by a power analysis. The analysis
determined the review of 50 charts should yield enough data to answer the research
question. However, there were only 42 client records that met inclusion criteria. Not
having enough patients from which to collect data as recommended by the power analysis
was identified as limitation. The 42 charts that did meet the inclusion criteria were used
for data extrapolation and analysis.

Project Design
Demographic variables (age, gender, and race) were collected from the facility’s
electronic records. Descriptive variables such as the patient’s primary cause of ESRD and
co-morbidities were obtained from the patient’s 2728 form in addition to recent hospital
and provider documentation. Other descriptive variables such as dates of BVM use,
prescribed anti-hypertensive medications, blood pressures, pre and post dialysis weights,
albumin, hemoglobin, and sodium levels were obtained from electronic records including
the facility laboratory’s website. Data on these variables measured before and after BVM
intervention was collected.
The identified variables were selected because they were expected to reveal
relationships that may assist in assessment and management of ECV status in the
hypertensive HD patient. The operational definition of HTN in HD patients was based on
the NKF-KDOQI guidelines (2006) of pre-dialysis BP readings of 140/90 mm/hg and
greater and post-dialysis readings of 130/80 mm/hg and greater.
The data collection tool summarized information pertaining to the demographic
and descriptive variables listed above. The collected data was evaluated at nominal and
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ratio levels. Nominal levels were used in the measurement of primary and co-morbid
diagnosis, anti-hypertensive medications, and demographic variables. Ratio levels were
used in reporting age, intradialytic weights, blood pressures, albumin, hemoglobin, and
sodium levels.

Subjects/Setting
The data was collected from the records of patients receiving treatment in the
hemodialysis unit. The data gathering and reviewing process took place during the
facility’s operating hours. Patient charts and documents were not removed from the
facility. A report was created to include variables needed for data analysis and was used
to populate the data collection tool. The inclusion criteria for the study’s subjects
included:
1. ESRD patients with at least 6 months of hemodialysis treatment history
2. History of hemodialysis at the current outpatient hemodialysis unit for 3 months
3. May be on the kidney transplant list
4. Documented diagnosis of hypertension on admission to dialysis unit or recent
diagnosis within the prior 6 months
5. History of antihypertensive therapy (current or discontinued) within the prior 3
months
6. Permanent patient of medical director or physicians who round on monthly basis.
Exclusion criteria included:
1. ESRD patient less than 18 years of age
2. Less than 3 months on hemodialysis
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3. No admitting diagnosis of hypertension or recent diagnosis within 6 months prior
to study initiation
4. Individuals prescribed anti-hypertensive therapy for secondary causes such as rate
control

H uman Subjects
Because this project was a chart review, no tests, procedures, or direct patient
contact was conducted, so there was no potential for harm to human subjects. The
university’s internal review board granted permission (IRB; see Appendix C) to proceed
with the study after review of the study, methods employed and procedures to protect the
patient and their information. .

Inst ruments
The purpose of the data collection tool (see Appendix B) was to analyze patient
data before and after the use of BVM in order to answer the research question, which
stated that the use of BVM along with the assessment of clinical parameters decreases
blood pressure by normalizing the ECV. The tool used codes to allow for statistical
analysis of data extracted and was piloted with sample of data of the studied variables.
An identification number, instead of the patient’s name or other identifying data, was
assigned to the patient and the list kept only by the researcher in a secure location. . If
confidentiality was breeched, a plan was in place to stop the breech, if possible, and
notify the facility’s management, patients, and other vested personnel. The Health
Insurance Portability and Accountability Act (HIPPA) provides for the privacy of
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personal health information. HIPPA criteria will be maintained via the study’s
confidentiality protocol as mentioned above.
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C H A PT E R 4: R ESU L TS

The purpose of this chapter is to present the findings of the Comparative Analysis
of Assessment of Excess Extracellular Volume in Hypertensive Hemodialysis Patients.
This comparative retrospective analysis is based on data from 42 patient files meeting the
inclusion and exclusion criteria outlined in Chapter 3.

Sample
Figure 1 illustrates the gender distribution of the sample of this study. Of the 42
participants, 60% were male and 40% were female. Figure 2 illustrates the national
average gender distribution in dialysis patients per the USRDS annual report (NIDDKD,
2008). This sample had more females than the reported national average. The mean age
of the participant was 58.6 years with a standard deviation of 16. Figure 3 illustrates the
sample by race. Of the 42 participants, 45% were Caucasian, 43% were
Hispanics/Latinos, 7% were of African descent, and 5% were Asian. Figure 4 illustrates
race of dialysis patients by national average.

Prima ry C ause of E nd Stage Renal Disease
Table 1 describes the primary cause of end stage renal disease (ESRD) for the
sample ( N = 42). This data was obtained from the patient’s End Stage Renal Disease
Medical Evidence Report (2728 form). Diabetes Mellitus was listed as the primary cause
of ESRD in 48% of the participants followed by hypertension/large vessel disease in 33%
of the participants. The sample had a higher incidence of hypertension compared to the
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Gender

40%

60%

Male (N=25)
Female (N=17)

Figure 1. Gender of dialysis patients (study participants).

Gender

45%
55%

Male (N=210,569)
Female (N=171,765)

Note. (N = 382,334).

Figure 2. Gender of dialysis patients (national average).
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Race
5%

7%

African Descent (N=3)
43%
45%

Caucasian (N=19)
Hispanic or Latino (N=18)

Asian (N=2)

Figure 3. Race of dialysis patients (study participants).
1%

Race

2%

14%
33%
African Descent (N = 141,995)
Caucasian (N=213,266)
Hispanic or Latino (N=61,081)
Asian/Pacific Islander (N=9602)

50%
Other/Unknown (N=3279)

National Institute of Diabetes and Digestive and Kidney Diseases. (2010). United States
Renal Data System. 2010 Annual Report. Atlas of Chronic Kidney Disease and End
Stage Renal Disease in the United States. Retrieved from http://www.usrds .org/atlas.htm
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Figure 4. Race of dialysis patients (national data).

National average (thirty-three percent compared to twenty-eight percent).
Glomerulonephritis was listed as the primary cause in 7% of the participants and
interstitial nephritis/ pyelonephritis and neoplasms/tumors were each the cause of ESRD
in 5% of participants. Secondary Glomerulonephritis was responsible for 2% of ESRD in
study participants. Table 2 describes the primary cause of ESRD per data obtained from
the USRDS (NIDDKD, 2008).

Table 1. Primary Cause of End Stage Renal Disease
Primary Cause of End Stage Renal Disease (Study Participants)

N
20
14
3
2
2
1

Primary Cause
Diabetes Mellitus
Hypertension/Large Vessel Disease
Glomerulonephritis
Interstitial Nephritis/Pyelonephritis
Neoplasm/Tumors
Secondary Glomerulonephritis

%
47.6
33
7.1
4.8
4.8
2.4

Table 2. Primary Cause of End Stage Renal Disease (national data)
Primary Cause of End Stage Renal Disease (national data)
Primary Cause
Diabetes Mellitus
Glomerulonephritis/ Secondary Glomerulonephritis
Hypertension/Large Vessel Disease
Other Known
Unknown
Interstitial Nephritis/Pyelonephritis
Missing Cause
Neoplasms/Tumors
Note. N = 382344.
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N
167,292
39,693
107,670
35,015
13,676
7,329
1,352
NA

%
42.8
10.8
28.2
9.2
3.6
1.9
0.4
NA

Co-Morbidities
Table 3 depicts the co-morbidities of the participants in the study ( N = 42)
obtained from the End Stage Renal Disease Medical Evidence Report. Co-morbidities are
diseases or disorders that coexist with a primary disease but also stand alone as a specific
disease. Diabetes Mellitus was the most frequent co-morbidity and was present in 48% of
the participants. Cardiovascular disease was present in 45% of the participants. Twentyone percent had chronic obstructive pulmonary disease and. nineteen percent of
participants had peripheral vascular disease. Amputations were documented in 17% of
the participants, Cerebral vascular disease was reported in 10% of the sample.
Malignancy/neoplasm and tobacco abuse were each diagnosed in 5% of the participants
and 2% had documentation of hepatic disease.

Table 3. Co-Morbidities of Study Participants
Co-Morbidities of Study Participants

N
20
19
4
9
8
7
2
2
1

Co-Morbidities
Diabetes Mellitus
Cardiovascular Disease
Cerebral Vascular Accident
Chronic Obstructive Pulmonary Disease
Peripheral Vascular Disease
Amputation
Malignancy/Neoplasm
Tobacco Abuse
Hepatic Disease

%
48
45
10
21
19
17
5
5
2

A ntihypertensive M edications
Table 4 lists the different classes of antihypertensive medication prescribed to the
participants. Fifty-four percent of the participants were prescribed beta-blockers and 37%
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received Dihydropyridine calcium channel blockers. Angiotensin converting enzyme
inhibitors were prescribed for 31%, of the participants. 24% received central agonists.
Twelve percent of participants took both angiotensin receptor blockers and diuretics.
Benzothiazepine calcium channel blockers were taken by 2% of the participants.

Table 4. Participants’ Antihypertensive Medications
Participant’s Antihypertensive Medications
Antihypertensive Class
Angiotensin Converting Enzyme-Inhibitors
Angiotensin Receptor Blockers
Beta Blockers
Calcium Channel Blockers (Benzothiazepines)
Calcium Channel Blockers (Dihydropyridines)
Central Agonists
Diuretics

N
13
5
22
1
15
10
5

%
31
12
52
2
36
24
12

Resea rch Q uestion
Analysis of this data was done to accept or reject the question “Are HD patients
who dialyze in a freestanding HD unit where BVM technology is used as an adjunctive
tool along with assessment of clinical parameters more likely to be normotensive (BP <
140/90 pre-dialysis. 130/80 post-dialysis) secondary to achieving and maintaining an
adequate dry weight?” In order to answer this question, statistical analyses were run using
SPSS statistical software. Descriptive statistics were run to obtain the minimum,
maximum, and mean of each variable and then paired samples test was completed on
paired variables. If the p value is less than or equal the mean correlation coefficient (p

value less than or equal to .05), the question was answered as yes. If the p value is
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greater than the mean correlation coefficient (p value greater than .05), the question was
answered as no.
To further explore the effect of the use of BVM on this client group, other
physiologic variables that are known to impact blood pressure were also examined. Thus,
tin addition to examination of pre and post BVM pre-dialysis systolic blood pressure,
pre-dialysis diastolic blood pressure, post-dialysis systolic blood pressure and postdialysis diastolic blood pressure, serum albumin, hemoglobin, and serum sodium were
also examined to evaluate if their reported values were be closer to or at the nationally set
goals with the use of the BVM to aid in the assistance of proper dry weight assessment
and attainment.
The paired sample t-test is a statistical test which tests the means of two samples
that are correlated. Paired sample t-test is used in before after studies, or when the
samples are the matched pairs. Pair samples statistics was run to assess variables pre and
post BVM use. Table 5 illustrates the variable, the mean, the matched pair’s mean and the
significance value.

Table 5. Descriptive Statistics for Pre- and Post-BVM Use
Descriptive Statistics for Pre- and Post-BVM Use
Pre BVM

Mean

Post BVM

Mean

Pre-dialysis
systolic blood
pressure
Pre-dialysis
diastolic blood
pressure
Post-dialysis
systolic blood
pressure

159.83

Pre-dialysis
systolic blood
pressure
Pre-dialysis
diastolic blood
pressure
Post-dialysis
systolic blood
pressure

78.6
130.21
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149.19

Matched
Pair’s Mean
10.64

Sig.
(2-tailed)
.000

74.74

3.87

.055

129.07

1.14

.692

Post dialysis
65.71
Post dialysis
65.5
.214
.899
diastolic blood
diastolic blood
pressure
pressure
Interdialytic
3.3
Interdialytic
3.2
.035
.586
weight gain
weight gain
Serum
3.698
Serum
3.705
-.007
.637
Albumin
Albumin
Hemoglobin
12
Hemoglobin
11.98
.057
.641
Serum Sodium
138.14
Serum Sodium
137.67
.476
.023
Figure 5 illustrates pre-treatment systolic blood pressure, pre and post BVM. The
significance value (p-value) was found to be .000. A paired samples t test revealed a
statistically reliable difference between the mean number pre BVM pre treatment systolic
blood pressure and the post BVM pre treatment systolic blood pressure. Figure 6
illustrates pre-treatment diastolic blood pressure, pre and post BVM. The significance
value (p-value) was found to be .055. A paired samples t test failed to reveal a
statistically reliable difference between the mean number pre BVM pre treatment
diastolic blood pressure and the post BVM pre treatment diastolic blood pressure. Figure
7 illustrates post-treatment systolic blood pressure, pre and post BVM. The significance
value (p-value) was found to be .692. A paired samples t test failed to reveal a
statistically significant difference between the mean number pre BVM post treatment
systolic blood pressure and the post BVM pre treatment systolic blood pressure.
Figure 8 illustrates post-treatment diastolic blood pressure, pre and post BVM.
The significance value (p-value) was found to be .899. A paired samples t test failed to
reveal a statistically reliable difference between the mean number pre BVM post
treatment diastolic blood pressure and the post BVM post treatment diastolic blood
pressure.
Figure 9 illustrates post-treatment systolic blood pressure, pre and post BVM. The
significance value was found to be .899. A paired samples t test failed to reveal a
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statistically reliable difference between the mean number pre BVM post treatment
diastolic blood pressure and the post BVM post treatment diastolic blood pressure..
Figure 10 illustrates interdialytic weight gain pre and post BVM. The significance value
was found to be .586. A paired samples t test failed to reveal a statistically reliable
difference between the mean numbers pre and post BVM interdialytic weight gain.
Figure 11 illustrates serum Albumin pre and post BVM. The significance value
(p-value) was found to be .637. A paired samples t test failed to reveal a statistically
reliable difference between the mean numbers pre and post BVM serum Albumin. Figure
12 illustrates the Hemoglobin pre and post BVM. The significance value was found to be
.641. A paired samples t test failed to reveal a statistically reliable difference between the
mean numbers pre and post BVM hemoglobin. Figure 13 illustrates serum Sodium, pre
and post BVM. The significance value was found to be .023. A paired samples t test
revealed a statistically reliable difference between the mean number pre and post BVM
serum sodium levels.
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Systolic Blood Pressure

Pre‐Treatment

140

145

150

155

160

Pre‐Treatment
Pre BVM: Pre‐Treatment
Systolic Blood Pressure

159.83

Post BVM: Pre‐Treatment
Systolic Blood Pressure

149.14

Figure 5. Pre-treatment systolic blood pressure: pre- and post-BVM.

Diastolic Blood Pressure

mm/hg

72

73

74

75

76
mm/hg

Pre BVM Pre Treatment DBP

78.6

Post BVM Pre Treatment DBP

74.74

Figure 6. Diastolic blood pressure pre- and post-BVM
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77

78

79

Post Treatment Systolic Blood Pressure

mm/hg

128.5

129

129.5

130

130.5

mm/hg
Pre BVM Post Treatment SBP

130.21

Post BVM Post Treatment SBP

129.07

Figure 7. Post-treatment systolic blood pressure.

Post Treatment Systolic Blood Pressure

mm/hg

128.5

129

129.5
mm/hg

Pre BVM Post Treatment SBP

130.21

Post BVM Post Treatment SBP

129.07

40

130

130.5

Figure 8. Posttreatment systolic blood pressure: Pre and postBVM.

Post Treatment Diastolic Blood Pressure

mm/hg

65.3

65.4

65.5

65.6

65.7

65.8

mm/hg
Pre BVM Post Treatment DBP

65.71

Post BVM Post Treatment DBP

65.5

Figure 9. Post-treatment diastolic blood pressure: Pre- and post-BVM.

Interdialytic Weight Gain

Kg

3.24

3.26

3.28
Kg

Pre BVM Post Interdialytic
Weight Gain

3.3

Post BVM Post Interdialytic
Weight Gain

3.264

Figure 10. Interdialytic weight gain: Pre and postBVM.
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Albumin

g/dl

3.694

3.696

3.698

3.7

3.702

3.704

3.706

12.04

12.06

g/dl
Pre BVM Alumin

3.698

Post BVM Albumin

3.705

Figure 11. Serum albumin: Pre and postBVM.

Hemoglobin

g/dl

11.94

11.96

11.98

12

12.02
g/dl

Pre BVM Hemoglobin

12.043

Post BVM Hemoglobin

11.986

Figure 12. Hemoglobin: Pre- and post-BVM.
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Serum Sodium

Sodium

137.4

137.6

137.8
Sodium

Pre BVM Sodium

138.14

Post BVM Sodium

137.67

Figure 13. Serum sodium: Pre- and post-BVM.
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138

138.2

C H A PT E R 5: D ISC USSI O N

The purpose of this comparative retrospective chart review was to assess the
possible correlation between control of hypertension in hemodialysis patients when fluid
management technology is used in conjunction with the assessment of clinical parameters
to manage DW. The effective management of hypertension in this population is highly
dependent on optimal fluid removal in manner that does not illicit intra, inter or post
dialytic complications such as nausea, vomiting, cramps in extremities, and fluid
resuscitation to treat hypotension (San Miguel, 2010). The problem of how best to assess
fluid status in ESRD patients has long plagued hemodialysis healthcare providers charged
with maintaining the balance among hypovolemia, euvolemia, and hypervolemia.
Hemodialysis nurses are responsible for carrying out the nephrologist and advanced
practitioner’s prescription for the dialysis treatment including the prescribed dry weight.
This is especially true for nephrology nurses since they are involved in the patient’s
treatment and may contribute either positively or negatively to the patient’s outcome.
Achieving optimal dry weight (DW) is often difficult in the outpatient
hemodialysis unit because of the lack of credible criteria to determine if the DW has been
achieved or whether a particular assessment is superior to another in assessing DW. A
prospective study of 150 HD patients found reduction in the DW has a positive effect on
blood pressure but had a negative impact on intravascular volume depletion to the point
of necessitating fluid resuscitation and clotting of the vascular access (Agarwal et al.,
2009).
Another variable that further confounds the management of DW is the patient.
HD patients are aware of the need to restrict their fluid intake, particularly those with
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little to none residual renal function. San Miguel (2010) stated that the sensation of thirst
is often results in behavioral activities such as drinking whereas the onset of drinking
results from motivational and cognitive processed that elicit the behavior. Fisher (2004)
observed that fluid restriction among HD patients creates an uncomfortable state of
ambivalence regarding drinking and Fisher conceptualized a model regarding fluid intake
in this population. The conceptualized model assumes there is tension between the need
to restrict fluid intake and the desire to drink and it is this focus on fluid restriction and an
increased sensation of thirst (Fisher, 2004). The accumulation of these sensations triggers
a sense of powerlessness and poor self-efficacy.
The direct relation between increased extracellular volume and hypertension led
to the formulation of the research question. The question stated: “Do hypertensive
patients who dialyze in dialysis unit where BVM technology is used along with the
assessment of clinical parameters more likely to be normotensive as defined by a pre
dialysis blood pressure of less than 140/90 and post dialysis blood pressure less than
130/80”? The following sections describe the study’s findings, limitations, conclusions,
implications to nursing, future research recommendations, and summary.
The data collection tool was tested and retested for usability through a pilot study.
The findings from the pilot study were then applied to the tool and another pilot study
was completed. At the conclusion of the pilot study, the tool was found to usable to
extrapolate data needed for analysis.

Demographics
The retrospective chart review was completed on 42 charts that met the inclusion
criteria. The demographics of the sample were representative of dialysis units in the
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United States and the sample was compared to the most recently retrieved data from the
United States Renal Data Systems (2010). Of the 42-hemodialysis patients 40.5% were
female and 59.5% compared to the national average of 44% females and 56% males.
The four races identified in the sample included: African descent, (includes
African Americans and Afro- Caribbean), Caucasian, Hispanic/Latino, and Asian. The
sample yielded 7.1% of African descent compared to the national average of 37.1%.
Caucasians comprised 45.2% compared to the national average of 55.8%.
Hispanic/Latinos made up 42.9% of the sample compared to the national average of 16%.
Lastly, 4.8% of the sample was Asian, which matched the national average. The sample
yielded a large percentage of Hispanic/Latino patients compared to the national average
(42.9% vs.16%) and conversely small percentage of African descent compared also to the
national average (7.1% vs.37.1%).
The data was obtained from a geographic location where the population was
59.5% Caucasian, 16.1% African descent, 21.5% Hispanic/Latino and with an Asian
population of less than 1%. The disproportionate percentage of African descent and
Hispanic/Latinos within the sample is seen as a factor which may have affected the
outcome of the study’s results especially in regards to the higher than national average of
diabetes mellitus seen in the Hispanic population.

Prima ry C ause of E nd Stage Renal Disease
The primary causes of end stage renal disease (ESRD) identified in the records of
patient reviewed for this study were diabetes mellitus, Glomerulonephritis, secondary
glomerulonephritis, interstitial nephritis/pyelonephritis, hypertension/large vessel disease,
and neoplasm/tumors. Diabetes mellitus was the primary cause of ESRD in 47.6% of the
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sample compared to the national average of 43.8%. Hypertension/large vessel disease
was listed as the primary cause of ESRD in 33% of the sample compared to the national
average of 28.3%. Glomerulonephritis was listed in 7.1% compared to the national
average of 10.4%. 2.4% of the sample listed Secondary Glomerulonephritis listed as the
primary cause of ESRD that was equal to the national average. Interstitial
nephritis/pyelonephritis was responsible for 4.8% of the cases as the primary cause of
ESRD in the sample compared to the national average of 3.2%. Lastly neoplasms/Tumors
were responsible for 4.8% of the causes compared to 2.4% national average. Diabetes
mellitus and hypertension/large vessel diseases were noted to be more prevalent in the
studied population, which may be secondary to the large Hispanic/Latino population in
the sample.

Co-Morbidities
Co-morbidities identified in this study included amputation, chronic obstructive
pulmonary disease (COPD), cerebral vascular accident (CVA), cardiovascular disease
(CVD), diabetes mellitus (DM), malignancy/neoplasm, hepatic disease, depression and
tobacco abuse. The co-morbidities were taken from the list provided on the 2728 form.
COPD, CVD, DM, and PVD had the highest occurrences of co-morbidities within the
study sample. Hypertension was not counted in co-morbidities, as it was an inclusion
criterion for the study.

A ntihypertensive M edication
The data revealed that 31% of the sample were prescribed ACE-I, 11.9% were
prescribed ARB. Calcium channel blockers (CCB) (all classes) are the most widely
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prescribed class of drugs for dialysis patients (NKF Clinical Practice Guidelines, 2006).
38.1% of the patients were prescribed CCB. CCB appears to be more effective when the
plasma volume is expanded and since hypertension in this population is a result of
extracellular volume expansion this class of medications has an advantage of reducing
hypertension hemodialysis patients.

Blood Pressu re M anagement
The comparative analysis of excess extracellular volume in hypertensive
hemodialysis (HD) patients sought to answer the question which asked “Are hypertensive
hemodialysis patients who dialyze in a freestanding dialysis unit, with blood volume
monitoring (BVM) technology available, more likely to be normotensive or closer to
normotension as defined by a pre dialysis blood pressure of less than 140/90 and post
dialysis blood pressure less than 130/80”? The paired samples T-test was run on the
collected data to assess the changes or lack thereof, to correctly answer the research
question within the paired data.
The four paired samples included: Pre-BVM: pre-dialysis SBP compared to postBVM: SBP, Pre-BVM: Pre-dialysis DBP compared to post-BVM: Pre-BVM postdialysis SBP to post-BVM: post-dialysis SBP, and Pre-BVM: post-dialysis DBP. The
records reviewed in this retrospective chart review demonstrated that the pre BVM pre
dialysis systolic blood pressure (SBP) had a mean of 160 mm/hg compared to a post
BVM pre dialysis SBP of 149 mm/hg. This result was found to be statistically significant
with a significance value (2-tailed) of .000 (p≤0.05) so the answer to the research
question “Are hypertensive hemodialysis patients who dialyze in a freestanding dialysis
unit, with BVM) technology available and utilized, more likely to be normotensive as
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defined by a pre dialysis blood pressure of less than 140/90 and post dialysis blood
pressure less than 130/80?” is yes in relation to pre dialysis systolic blood pressure.
This statistically significant finding supports the correlation between reduction in
the HD patient’s extracellular volume and improved blood pressure control. The
reduction of pre-dialysis SBP was significant because Agarwal (2006) made the
observation that most patients on hemodialysis have systolic hypertension that may or
may not coexist with diastolic hypertension. Pre dialysis systolic blood pressure is
superior to post dialysis blood pressure as a screening tool for detecting hypertension in
dialysis patients (Charra, 2007).
The pre BVM post dialysis SBP mean was 130 mm/hg and the post BVM post
dialysis mean was 129 mm/hg. There was no statistical significance noted (.692). The
answer to the research question “Are hypertensive hemodialysis patients who dialyze in a
freestanding dialysis unit, with BVM) technology available and used, more likely to be
normotensive as defined by a pre dialysis blood pressure of less than 140/90 and post
dialysis blood pressure less than 130/80?” is no in relation to systolic blood pressure
before and after BVM use.
However, it is important to note that both values met guidelines of a post dialysis
SBP of less than or equal to 130 mm/hg. This finding leads one to speculate that the
availability and use of the BVM technology may be a reason why this goal is attained.
The pre BVM pre dialysis diastolic blood pressure was found to have a mean of
79 mm/hg compared to the post BVM pre dialysis DBP mean of 75 mm/hg. Again, this
value was not statically significant (.055). The answer to the research question “Are
hypertensive hemodialysis patients who dialyze in a freestanding dialysis unit, with
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BVM) technology available and used, more likely to be normotensive as defined by a pre
dialysis blood pressure of less than 140/90 and post dialysis blood pressure less than
130/80?” is, again, no in relation diastolic blood pressure before and after BVM use.
However, again, this may have clinical significance because national
guidelines/recommendations were met for systolic and diastolic readings.
The pre BVM post dialysis DBP presented with a mean of 67 mm/hg compared to
post BVM post dialysis DBP of 66 mm/hg that is once again not statistically significant
(.899). The answer to the research question “Are hypertensive hemodialysis patients who
dialyze in a freestanding dialysis unit, with BVM) technology available and used, more
likely to be normotensive as defined by a pre dialysis blood pressure of less than 140/90
and post dialysis blood pressure less than 130/80?” is no in relation to pre and post
dialysis diastolic blood pressure. However, it is important to note that the diastolic values
at both points met guidelines and it is important to remember many patients have systolic
hypertension without diastolic hypertension.

O ther O bservations
While not related to the specific research question, the following summarizes
observations based on data collected in association with this study.
Interdialytic W eight G ain
The mean pre BVM interdialytic weight gain (IDWG) average was 3.3kg
compared to the mean of 3.3kg post BVM intervention. The findings were not statically
significant (p≤0.05). NKF-KDOQI (2006) state the average IDWG should be less than or
equal to 3kg. Kalantar-Zadeh et al. (2009) found in long-term hemodialysis patients, a
higher IDWG is associated with poor survival and increased cardiovascular death. Most
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importantly they found the patients with the lowest interdialytic fluid retention had the
greatest risk of survival observed across the subgroups of hemodialysis patients.
Can the use of the BVM technology used in conjunction with the assessment of
clinical parameters help patients control their intradialytic weight gain? When a patient is
eulvolemic there may be an increase in energy that leads to an overall sense of wellbeing,
which may mitigate improved adherence with dietary fluid restriction. The BVM may be
effective in attaining the correct dry weight by showing a visualization of the patient’s
current fluid status and allowing active patient participation in their care. Lindberg (2008)
made the observation that pragmatic and effective ways of helping patients with fluid
management are lacking and the results o of intervention studies in this area have in
general been disappointing. Baraz (2010) conducted a randomized clinical trial that
provided educational video two times a week for two weeks. The video emphasized
ESRD dietary management, identification of appropriate provisions, fluid restrictions,
and consequences of fluid overload. The outcome was fluid overload was reduced. This
study validated the importance of education and patient involvement to impact outcomes.
A lbumin
The pre BVM mean for serum Albumin was 3.7 g/dl and the post BVM serum
Albumin mean was also 3.7. This finding was not statistically significant because of a p
value ≥ 0.5 (p = .637). San Miguel (2010) stated that assessment of Albumin is pivotal, in
combination of other clinical parameters, when assessing dry weight (DW). Particular
attention should be paid to patients with a low Albumin (<3.4 g/dl) because these patients
are likely to show signs of not tolerating fluid removal with HD such as hypotension and
cramps despite the presence of excess extracellular volume (2010).
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Sodium
The pre BVM mean for sodium was 138 and the post BVM mean was 137. The
finding was found to be statistically significant with a p value of .023. With the removal
of ECV to achieve the prescribed dry weight there is a decrease in the serum sodium as
the ECV normalizes (2007). Sodium is often the forgotten element in managing a
patient’s ECV and dry weight but assessment to serum sodium levels may assist in ECV
and dry weight management by monitoring fluctuations in reported values. During the
dialysis process often the sodium is increased to alleviate intradialytic symptoms such as
hypotension and cramping. The hemodialysis machine has the ability to deliver between
135-145mEq/L of sodium during a dialysis treatment (2007).
Agarwal (2006) used the example of a patient who weighs 72kg. The total body
water is estimated at 43L. If the pre dialysis sodium concentration is 135mEq/L and the
patient is dialyzed against 145mEq/L, a total of 430mEq of sodium will be delivered to
the patient during the treatment during a typical of 210-240 minutes. This is equal to 3kg
of interdialytic weight gain and this type of weight gain is directly responsible for
increased thirst and, interdialytic hypotension (Agarwal, 2006). In order to end this cycle
interdialytic sodium delivery should be based on individual patient needs. The take away
message is reinforcing the importance of the sodium-restricted diet in dialysis patients as
another method to effectively control intradialytic fluid weight gain and hypertension.
Researchers found that adherence to a 2 gm sodium diet would decrease
interdialytic weight gain by controlling thirst and limiting weight gain may alleviate the
large variations in BP and possibly prevent intradialytic hypotensive symptoms
(Agarwal, 2006). Agarwal (2006) states a patient who follows a 2 gm sodium diet would
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most likely have an interdialytic weight gain of 1.25kg over 48 hours and 1.9kg in 72
hours. Sodium restriction is beneficial because it may assist in limiting large interdialytic
weight gains and mitigates the large swings in blood pressures that may decrease
incidences of intradialytic hypotensive symptoms (Agarwal, 2006).
H emoglobin
The pre and post BVM hemoglobin (Hgb) mean was 12 mg/dl with a p value of
.641, which was not statistically significant. However the Hgb values did meet national
guidelines and recommendations from the NFK-KDOQI guidelines that target Hgb
ranges between 10-12 g/dl for dialysis patients. The BVM utilizes the patient’s real time
Hgb to estimate the patient’s extracellular status given Hgb variability changes in the
patient’s fluid levels (Hlebovy, 2003).

L imitations
Limitations were identified in this study. All of the records reviewed were from
patients at one freestanding outpatient hemodialysis unit chosen by a convenience
sampling method. The sample size was small (N=42) and did not meet the number (50)
mandated by the power analysis.
The dialysis unit’s population of 45.2% Caucasian, 42.9% Hispanic/Latino, and
7.1% African descent was not representative of the national average. This is seen as a
limitation if results are to be applied nationally. The large Hispanic group may have been
responsible for the larger percentage of diabetes mellitus and hypertension. The small
percentage of African descent patients may have limited the power of the BVM
intervention as various studies have found a higher prevalence of volume dependent
hypertension among those of African descent (Kalantar-Zadeh et al.2009 & Baraz, 2010).
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Another limitation was the inability to collect patient’s pre and post BVM glucose
readings because the unit monitors Hemoglobin A1C levels four times a year in known
diabetic patients only. There were also no current serum glucose levels. Elevated serum
glucose levels may be a cause of excess ECV due to increased serum osmolarity.
The limited use of the BVM in the facility used was also identified as a limitation.
Optimally, the BVM should be used every 2-4 weeks on all patients to continue ongoing
ECV management. It was also not possible to document the level of education of staff on
the use of the BVM or the degree to which individual nurses used this data when making
decisions during any one-dialysis event. The staff must be retrained and checked off on
the proper use and interpretation of data obtained from the BVM in order to effectively
use this technology to assess and manage ECV. Finally, research bias was a limitation.
The bias of this author is that the primary etiology hypertension in most hemodialysis
patients is resultant of excess ECV and diligent attention must be paid to this detail.
These limitations have been acknowledged.

Conclusion
The findings of this study suggest the use of the use BVM is effective in the
management of hypertension in hemodialysis patients with excess ECV. There were
statically significant positive changes in post BVM pre dialysis systolic pressures, which
were closer to the national guidelines goal of 140 mm/hg. A statically significant change
was also found in pre vs. post BVM serum sodium. The data also revealed that the mean
pre and post BVM diastolic blood pressure, sodium, and hemoglobin were all within the
goals of national guidelines. This finding lends support of the belief that the use of BVM
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technology may assist with normalization of blood pressure and more effective
management of excess ECV.

Implications for Nu rsing
The effectiveness of the use of the BVM to manage hypertensive hemodialysis
patients is evident in this comparative descriptive study. Nephrologists and Advanced
practitioners (Nurse practitioners [NP] and physician assistants [PA] will prescribe the
dialysis prescription and consultation but the day-to-day management, including the safe
execution of evidence based treatment, responsibility falls on the nurse. This study should
help improve this process as these providers combine physical assessment parameters and
BVM technology to formulate the protocol for specific patients.
This also has implications for nurses actually supervising the dialysis event and
making bedside decisions (often without the ARNP or physician provider present) as to
when and how to end a session. Lindberg (2008) found that one in five HD patients were
being dialyzed to an inadequate DW. A possible explanation may be lack of knowledge
of the nursing staff about how to use the BVM data to make decisions about how to best
achieve DW. In addition nurses may need education about how to use this data without
fear of causing the patient undue discomfort because of removal of fluid either in a
manner, which is too rapid possibly resulting in nausea, vomiting, or leg cramps.
An expert dialysis nurse knows how the variables of intradialytic weight gain and
rate of fluid removal (ultrafitration rate) are key quality indicators for qualitynephrology
nursing care. They know how to (and actually do) assess these factors on a regular basis.
This retrospective study did not look at individual clinical assessment parameters used by
the nursing staff (such as edema, or adventitious lung sounds) and it is important to note
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nursing support is critical to assisting patients in developing proficiency in certain skills
and tasks.
Due to the increasing prevalence of chronic kidney disease (CKD) and ESRD in
the United States and excess ECV management is imperative to decrease patient
morbidity and mortality. The belief that fluid overload is a normal condition in most HD
patients is a paradigm that must be discarded in favor of a new paradigm that emphasizes
cardiovascular disease is the leading cause of mortality with over hydration as a major
contributing factor (Linberg, 2008). The nephrology nurse and the nephrology Advanced
Practitioner have regular and frequent interactions with the HD patient and hence have an
opportunity to educate the patient about fluid, sodium, and hypertension management
(2008). It is the hope of this researcher that the findings will be used to imporve protocols
to manage ECV in the HD patient.
Advanced practice nurses in nephrology, in particular those with a doctorate in
nursing practice (DNP), will be able to take the information from this study and improve
routine evaluation of patients’ ECV status and possibly adjustment of the dry weight
through the use of protocols. Lindberg (2008) observed that advanced practice nurses
often provide expert care, which results in optimized patient self-management. DNP may
take the reigns of to educate advanced practice nurses, nephrology nurses, and ancillary
staff on the signs and symptoms of ECV excess. Effective ECV management is achieved
ongoing assessment with the goal of getting the patient as close to normotension as
possible while decreasing the patient’s pill burden by discontinuing antihypertensive
medications as warranted.
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Dialysis staff must be trained that if the patient begins to experience hypotension,
cramps, and/or nausea and/or vomiting to notify the nursing staff or the advanced
practitioner nurse to make adjustments to the rate of fluid removal, medications, and /or
dry weight. All those involved in the care of the dialysis patient must be involved must
empower the patient by providing ongoing education regarding ECV and blood pressure
management along with information regarding sodium and fluid restrictions.

Suggestions for F utu re Resea rch
Future research is recommended for excess ECV management in hypertensive HD
patients with the hope of decreasing morbidity and mortality associated with
cardiovascular disease. The same study may be duplicated in units with a population
closer to the national average to better assess the use of the use of BVM technology in
hypertensive hemodialysis patients in which secondary causes have been excluded. The
BVM is expensive so there are limited quantities available in select HD units but a
protocol in which BVM is used weekly may seek to decrease hospitalizations and
morbidity and mortality rates. Research that would continue to reinforce the role of
excess ECV in dialysis patients is needed to decrease morbidity and mortality in this
vulnerable population. A much larger prospective study in which the glucose levels are
measured in correlation with hypertension and increased ECV (either by hemoglobin
A1C or serum glucose) may capture variables not captured in this study.
The NKF-KDOQI guidelines (2006) state drugs that inhibit the renin-angiotensin
system (RAS), such as angiotensin converting enzyme inhibitors (ACE-I) or angiotensin
II-receptor blockers (ARB) are preferred in the management of hypertension in dialysis
patients because they cause greater regression of left ventricular hypertrophy (LVH),
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reduce sympathetic nerve activity, reduce pulse wave velocity, may improve endothelial
function, and may reduce oxidative stress (Agarwal, 2007). A follow up study with a
larger sample may examine if the findings of the BVM along with certain
antihypertensive medications to assess which single medication or combination of
medications will improve make no change, or possibly worsen patient outcomes.

Summa ry
The reported outcomes of this project are relevant to the management of
hypertensive dialysis patients with excess ECV yet there is vast room for improvement in
this arena. Individuals that will benefit from the outcomes of this study include
physicians, advanced practice practitioners, nephrology nurses and ancillary staff who
were unaware of the importance of excess ECV in the management of HTN in dialysis
patients. Familiarity with the pathophysiology of HTN in this population will lead to
decrease pill burden, decreased hospitalizations, and decreased morbidity and mortality.
The outcomes revealed descriptive information about the management of ECV in
hypertensive HD patients. Extrapolated information included the statistically significant
reduction in pre dialysis systolic blood pressure and post BVM serum sodium. These
findings may be used as the foundation for future works of research in dialysis patients
and all those with issues of excess ECV such as those with heart and liver failure.
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A PP E N D I X A : 2728 F O R M
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A PP E N D I X B : D A T A C O L L E C T I O N T O O L
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DIABETES
Type II, adult-onset type or unspecified type diabetes
Type I, juvenile type, ketosis prone diabetes
CYSTIC/HEREDITARY/CONGENITAL DISEASES
Polycystic kidneys, adult type (dominant)
Polycystic, infantile (recessive)
Medullary cystic disease, including nephronophthisis
Tuberous sclerosis
Hereditary nephritis, Alport’s syndrome
Cystinosis
Primary oxalosis
Fabry’s disease
Congenital nephrotic syndrome
Drash syndrome, mesangial sclerosis
Congenital obstructive uropathy
Renal hypoplasia, dysplasia, oligonephronia
Prune belly syndrome
Hereditary/familial nephropathy
GLOMERULONEPHRITIS
Glomerulonephritis (GN)
(histologically not examined)
Focal glomerulosclerosis, focal sclerosing GN
Membranous nephropathy
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Membranoproliferative GN type 1, diffuse MPGN
Dense deposit disease, MPGN type 2
IgA nephropathy, Berger’s disease
(Proven by immunofluorescence)
IgM nephropathy (proven by immunofluorescence)
Rapidly progressive GN
Goodpasture’s Syndrome
Post infectious GN, SBE
Other proliferative GN
SECONDARY GN/VASCULITIS
Lupus erythematosus, (SLE nephritis)
Henoch-Schonlein syndrome
Scleroderma
Hemolytic uremic syndrome
Polyarteritis
Wegener’s granulomatosis
Nephropathy due to heroin abuse and related drugs
Vasculitis and its derivatives
Secondary GN, other
HYPERTENSION/LARGE VESSEL DISEASE
Renal disease due to hypertension (no primary renal disease)
Renal artery stenosis
Renal artery occlusion
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Cholesterol emboli, renal emboli
INTERSTITIAL NEPHRITIS/PYELONEPHRITIS
Analgesic abuse
Radiation nephritis
Lead nephropathy
Nephropathy caused by other agents
Gouty nephropathy
Light chain nephropathy
Amyloidosis
NEOPLASMS/TUMORS
Renal tumor (malignant)
Urinary tract tumor (malignant)
Renal tumor (benign)
Urinary tract tumor (benign)
Renal tumor (unspecified)
Urinary tract tumor (unspecified)
Lymphoma of kidneys
Multiple myeloma
Complication post bone marrow or other transplant
MISCELLANEOUS CONDITIONS
Sickle cell disease/anemia
Sickle cell trait and other sickle cell (HbS/Hb other)
Post partum renal failure
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AIDS nephropathy
Traumatic or surgical loss of kidney(s)
Hepatorenal syndrome
Tubular necrosis (no recovery)
Other renal disorders
Etiology uncertain
Co-Morbid Conditions (Current or during last 10 years)
Congestive heart failure
Ischemic heart disease, CAD
Myocardial infarction
Cardiac arrest
Cardiac dysrhythmia
Pericarditis
Cerebrovascular disease, CVA, TIA
Peripheral vascular disease
History of hypertension
Diabetes (primary or contributing)
Diabetes, currently on insulin
Chronic obstructive pulmonary disease
Tobacco use (current smoker)
Malignant neoplasm, Cancer
Alcohol dependence
Drug dependence
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HIV positive status
AIDS
Amputation
Inability to ambulate
Inability to transfer

71

A PP E N D I X C : U N I V E RSI T Y O F C E N T R A L F L O R I D A I NST I T U T I O N A L
R E V I E W B O A R D A PPR O V A L

72

73

R E F E R E N C ES

Agarwal, R. (2003). Systolic hypertension in hemodialysis patients. Seminars in Dialysis,
16(3), 208-213.
Agarwal, R. (2005). Hypertension and survival in chronic hemodialysis patients—past
lessons and future opportunities. Kidney International, 67(1), 1-13.
Agarwal, R. (2007). How should hypertension be assessed and managed in hemodialysis
patients? Seminars in Dialysis , 20(5), 402-405. Retrieved from:
http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=17897244
&site=ehost-live
Agarwal, R., Alborzi, P., Satyan, S., & Light, R. P. (2009). Dry-weight reduction in
hypertensive hemodialysis patients (DRIP): A randomized, controlled trial.
Hypertension, 53(3), 500
Agarwal, R., Andersen, M. J., & Pratt, J. H. (2008). The Importance of pedal edema in
hemodialysis patients. Clinical Journal of the A merican Society of Nephrology,
3(1), 153
Agarwal, R., Kelley, K., & Light, R. P. (2008). Diagnostic utility of blood volume
monitoring in hemodialysis patients. A merican Journal of Kidney Diseases, 51(2),
242-254
Agarwal, R., Nissenson, A. R., Batlle, D., Coyne, D. W., Trout, J. R., & Warnock, D. G.
(2003). Prevalence, teatment, and control of hypertension in chronic hemodialysis
patients in the United States. The A merican Journal of Medicine, 115(4), 291-297
Bonner, A., & Walker, A. (2004). Nephrology Nursing: Blurring the boundaries: the
reality of expert practice. Journal of Clinical Nursing, 13(2), 210-218.
Borsboom, H., Smans, L., Cramer, M., Kelder, J., Kooistra, M., Vos, P., et al. (2005).
Long-term blood pressure monitoring and echocardiographic fndings in patients
with end-stage renal disease: reverse epidemiology explained? The Netherlands
Journal of Medicine, 65(10)
Brady, B. A., Tucker, C. M., Alfino, P. A., Tarrant, D. G., & Finlayson, G. C. (1997). An
investigation of factors associated with fluid adherence among hemodialysis
patients: a self-efficacy theory based approach. Annals of Behavioral Medicine,
19(4), 339-343.
Charra, B. (2007). Fluid balance, dry weight, and blood pressure in dialysis.
Hemodialysis International. Symposium on Home Hemodialysis, 11(1), 21-31
Retrieved on March 6, 2010 from:
http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=17257351
&site=ehost-live
Chen, J., Gul, A., & Sarnak, M. J. (2006). Management of intradialytic hypertension: the
ongoing challenge. Seminars in Dialysis, 19(2), 141-145. Retrieved March 6,

74

2010, from http://search.ebscohost.com/login.aspx?direct=true&db
=cmedm&AN=16551292&site=ehost-live
Chou, K., Lee, P., Chen, C., Chiou, C., Hsu, C., Chung, H., et al. (2006). Physiological
changes during hemodialysis in patients with intradialysis hypertension. Kidney
International , 69(10), 1833-1838. Retrieved on March 6, 2010 from:
http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=16691262
&site=ehost-live
Christensen, A. J., Moran, P. J., Lawton, W. J., Stallman, D., & Voigts, A. L. (1997).
Monitoring attentional style and medical regimen adherence in hemodialysis
patients. Health Psychology: Official Journal of the Division of Health
Psychology, American Psychological Association, 16(3), 256-262.
Christensen, A. J., Smith, T. W., Turner, C. W., & Cundick, K. E. (1994). Patient
adherence and adjustment in renal dialysis: a person treatment interactive
approach. Journal of Behavioral Medicine, 17(6), 549-566.
Curtin, R., Svarstad, B., & Keller, T. (1999). Hemodialysis patients' noncompliance with
oral medication. A merican Nephrology Nursing Association Journal , 26(3), 307316.
Denhaerynck, K., Manhaeve, D., Dobbels, F., Garzoni, D., Nolte, C., & De Geest, S.
(2007). Prevalence and consequences of nonadherence to hemodialysis regimens.
A merican Journal of Critical Care, 16(3), 222.
Donauer, J. (2004). Hemodialysis‐Induced Hypotension: Impact of technologic
advances. Seminars in Dialysis. 17(5) 333-335.
Fagugli, R. M., Reboldi, G., Quintaliani, G., Pasini, P., Ciao, G., Cicconi, B., et al.
(2001). Short daily hemodialysis: blood pressure control and left ventricular mass
reduction in hypertensive hemodialysis patients. American Journal of Kidney
Diseases: The Official Journal of the National Kidney Foundation, 38(2), 371376. Retrieved on March 6, 2010 from:
http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=11479164
&site=ehost-live
Fan, P., Shu, C., Shiang, J., Kuo, T., & Lung, F. (2006). Hypertension: a possible
vulnerability marker for depression in patients with end-stage renal disease.
Nephron.Clinical Practice, 102(1), 43-50. Retrieved on March 6, 2010 from:
http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=16174990
&site=ehost-live
Flanigan, M. (2004). Dialysate composition and hemodialysis hypertension. Seminars in
Dialysis, 17(4), 279-283. Retrieved on March 6, 2010 from:
http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=15250918
&site=ehost-live
Fleischmann, E., Teal, N., Dudley, J., May, W., Bower, J. D., & Salahudeen, A. K.
(1999). Influence of excess weight on mortality and hospital stay in 1346
hemodialysis patients. Kidney International , 55(4), 1560-1567.

75

Foley, R. N., & Collins, A. J. (2007). End-stage renal disease in the United States: An
update from the united states renal data system. Journal of the A merican Society
of Nephrology, 18(10), 2644.
Foley, R. N., Parfrey, P. S., Harnett, J. D., Kent, G. M., Murray, D. C., & Barre, P. E.
(1996). Impact of hypertension on cardiomyopathy, morbidity and mortality in
end-stage renal disease. Kidney International , 49(5), 1379.
Gilbertson, D. T., Liu, J., Xue, J. L., Louis, T. A., Solid, C. A., Ebben, J. P., et al. (2005).
Projecting the number of patients with end-stage renal disease in the United States
to the year 2015. Journal of the A merican Society of Nephrology, 16(12), 3736.
Haynes, R. B., McDonald, H. P., & Garg, A. X. (2002). Helping patients follow
prescribed treatment clinical applications. Journal of the A merican Medical
Associaion, 288(22), 2880-2883.
Heerspink, H. J. L., Ninomiya, T., Zoungas, S., De Zeeuw, D., Grobbee, D. E., Jardine,
M. J., et al. (2009). Effect of lowering blood pressure on cardiovascular events
and mortality in patients on dialysis: a systematic review and meta-analysis of
randomized controlled trials. Lancet, 373(9668), 1009.
Hlebovy, D. (2006). Hemodialysis Special interest group networking session: fluid
management: moving and removing fluid during hemodialysis. Nephrology
Nursing Journal: Journal of the A merican Nephrology Nurses' Association, 33(4),
441-445.
Hörl, M. P., & Hörl, W. H. (2004). Drug Therapy for Hypertension in Hemodialysis
Patients. Seminars in Dialysis, 17(4), 288-294. Retrieved on March 6, 2010 from:
http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=15250920
&site=ehost-live
Horne, R., & Weinman, J. (1999). Patients' Beliefs about Prescribed Medicines and their
Role in Adherence to Treatment in Chronic Physical Illness. Journal of
Psychosomatic Research, 47(6), 555-567.
Inrig JK, Oddone EZ, Hasselblad V, Gillespie B, Patel UD, Reddan D, Toto R,
Himmelfarb J, Winchester JF, Stivelman J, Lindsay RM, Szczech LA, (2007).
Association of Intradialytic Blood Pressure Changes with Hospitalization and
Mortality Rates in Prevalent ESRD Patients. Kidney International , 71(5), 454461.
Izzo, J. L., Sica, D. A., & Black, H. R. (2008). Hypertension primer: The Essentials of
High Blood Pressure: Basic Science, Population Science, and Clinical
Management (4th ed.). Philadelphia, Pa: Lippincott Williams & Wilkins.
Jaeger, J. Q., & Mehta, R. L. (1999). Assessment of dry weight in hemodialysis: an
overview. Journal of the A merican Society of Nephrology, 10(2), 392 - 403.
Jindal, Kailash, Chan, Christopher T., Deziel, Clement, Hirsch, David, Soroka, Steven
D., Tonelli, Marcello, Culleton, Bruce F. (2006). Management of blood pressure
in hemodialysis patients. Journal of the A merican Society of Nephrology, 17(3)

76

Kalantar-Zadeh, K., Kilpatrick, R. D., McAllister, C. J., Greenland, S., & Kopple, J. D.
(2005). Reverse epidemiology of hypertension and cardiovascular death in the
hemodialysis population. Hypertension, 45(4), 811-817.
Kammerer, J., Garry, G., Hartigan, M., Carter, B., & Erlich, L. (2007). Adherence in
patients on dialysis: strategies for success. Nephrology Nursing Journal , 34(5).
Kauric-Klein, Z., & Artinian, N. (2007). Improving blood pressure control in
hypertensive hemodialysis patients. CANNT Journal . 17(4), 24-8, 31-6.
Kiss, I., Farsang, C., & Rodicio, J. L. (2005). Treatment of hypertension in dialyzed
patients. Journal of Hypertension, 23(1), 222.
Kooman, J. P., van der Sande, F., Leunissen, K., & Locatelli, F. (2003). Sodium balance
in hemodialysis therapy. Seminars in Dialysis. 6(5) 351-355.
Koomans, H., A., Blankestijn, P., J. (1995). Blood volume preservation in dialysis: tools
and strategies. Nephrology Dialysis Transplantation, 10(10), 1791.
Kugler, C., Vlaminck, H., Haverich, A., & Maes, B. (2005). Nonadherence with diet and
fluid restrictions among adults having hemodialysis. Journal of Nursing
Scholarship, 37(1), 25.
Kutner, N. G. (2001). Improving compliance in dialysis patients: does anything work?
Seminars in Dialysis. 14(5) 324-327.
Kyngas, H., Duffy, M. E., & Kroll, T. (2000). Conceptual analysis of compliance.
Journal of Clinical Nursing, 9(1), 5-12.
Landry, D. W., & Oliver, J. A. (2006). Blood Pressure Instability during Hemodialysis.
Kidney International , 69(10), 1710-1711. Retrieved on March 6, 2010 from:
:http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=16688188
&site=ehost-live
Lazar, A. E., Smith, M. C., & Rahman, M. (2004). Blood pressure measurement in
hemodialysis patients. Seminars in Dialysis, 17(4), 250-254. Retrieved on March
6, 2010 from:
http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=15250912
&site=ehost-live
Lazarus, J. M., Hakim, R. M., Maddux, F. W., & Amedia, C.,Jr. (2005). The emperor has
no clothes (but has a catheter): A perspective on the state of chronic kidney
disease care. Nephrology News & Issues, 19(12), 45. Retrieved from
http://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=2009072534&s
ite=ehost-live
Leggat, J. E. (2005). Adherence with dialysis: A focus on mortality risk. Paper presented
at the Seminars in Dialysis, 18(2) 137-141.
Lucas, M. F., Quereda, C., Teruel, J. L., Orte, L., Marcen, R., & Ortuno, J. (2003). Effect
of hypertension before beginning dialysis on survival of hemodialysis patients.
A merican Journal of Kidney Diseases : The Official Journal of the National
Kidney Foundation, 41(4), 814-821.

77

Lynn, K. L. (2004). Hypertension and survival in hemodialysis patients. Seminars in
Dialysis, 17(4), 270-274. Retrieved from
http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=15250916
&site=ehost-live
Mailloux, L. U. (2001). Hypertension in chronic renal failure and esrd: prevalence,
pathophysiology, and outcomes. Seminars in Nephrology, 21(2), 146-156.
Mallamaci, F., Tripepi, G., Malatino, L., & Zoccali, C. (2002). Inflammation and
outcome in end-stage renal failure: does female gender constitute a survival
advantage? Kidney International , 62(5), 1791-1798.
Mc Cance K., L., Huether S., E. (1998). The biologic Basis for Disease in Adults and
Children. St. Louis Missouri: Mosby.
Medicare and Medicaid Services, Department of Health and Human Services. (2008).
Medicare and Medicaid Programs: Conditions for Coverage for End-Stage
Renal Disease Facilities: Final Rule Federal Register. Retreived onMarch 6, 2010,
from: www.cms.gov/cfcsandcops/downloads/esrdfinalrule0415.pdf
Mensah, G. A., Croft, J. B., & Giles, W. H. (2002). The heart, kidney, and brain as target
organs in hypertension. Cardiology Clinics, 20(2), 225-247.
Morgan, L. (2000). A decade review: Methods to improve adherence to the treatment
regimen among hemodialysis patients. Nephrology Nursing Journal , 27(3), 299304.
National Heart, Lung, and Blood Institute. (2003). The seventh report of the joint national
committee on prevention, detection, evaluation, and treatment of high blood
pressure. Retrieved October 15, 2008, from
http://www.nhlbi.nih.gov/guidelines/hypertension/
National Kidney Foundation Kidney Dialysis Quality Initiative Outcomes (2005).
Clinical practice guidelines on hypertension and antihypertensive therapy in
chronic kidney disease. Retrieved from:
http://www.kidney.org/professionals/KDOQI/guidelines_bp/executive_summary.
htm on March 6, 2010.
Nissenson, A. R. (2003). Disease management improves outcomes in patients with CKD.
Nephrology News & Issues, 17(9), 15. Retrieved on March 6, 2010 from:
:http://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=2003156486&
site=ehost-live
Pliskin, J. S., Steinman, T. I., Lowrie, E. G., & Beck, C. H. (1976). Hemodialysis:
projecting future bed needs. deterministic and probabilistic forecasting.
Computers and Biomedical Research. 9(4), 317-336.
Polit, D.R. & Beck, C.T. (2008). Nursing research: Generating and assessing evidence
for nursing practice (8th ed.). New York: Wolter Kluwer/Lippincott Williams
&Wilkins.
Purcell, W., Manias, E., Williams, A., & Walker, R. (2004). accurate dry weight
assessment: reducing the incidence of hypertension and cardiac disease in patients

78

on hemodialysis. Nephrology Nursing Journal :, 31(6), 631. Retrieved from
http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=15686326
&site=ehost-live
Rahman, M., Dixit A., Donley, V., Gupta, S., Hanslik, T., LACSON, E., et al. (1999).
Factors associated with inadequate blood pressure control in hypertensive
hemodialysis patients. A merican Journal of Kidney Diseases, 33(3), 498-506.
Rahman, M., & Griffin, V. (2004). Patterns of antihypertensive medication use in
hemodialysis Patients. A merican Journal of Health-System Pharmacy: AJHP:
Official Journal of the A merican Society of Health-System Pharmacists, 61(14),
1473-1478. Retrieved on March 6, 2010 from:
http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=15332695
&site=ehost-live
Rahman, M., & Smith, M. C. (2001). Hypertension in hemodialysis patients. Current
Hypertension Reports, 3(6), 496-502.
Rodriguez, H. J., Domenici, R., Diroll, A., & Goykhman, I. (2005). Assessment of dry
weight by monitoring changes in blood volume during hemodialysis using Critline. Kidney International, 68(2), 854-861.
Ross, E. A., Pittman, T. B., & Koo, L. C. (2002). Strategy for the treatment of
noncompliant hypertensive hemodialysis patients. The International Journal of
Artificial Organs, 25(11), 1061-1065.
Rubinger, D., Backenroth, R., Pollak, A., & Sapoznikov, D. (2008). Blood pressure and
heart rate variability in patients on conventional or sodium-profiling
hemodialysis. Renal Failure, 30(3), 277-286. Retrieved on March 6, 2010 from:
http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=18350447
&site=ehost-live
Savage, T., Fabbian, F., Giles, M., Tomson, C., & Raine, A. (1997). Interdialytic weight
gain and 48-h blood pressure in haemodialysis patients. Nephrology Dialysis
Transplantation, 12(11), 2308.
Shaldon, S. (2002). Dietary salt restriction and drug-free treatment of hypertension in
ESRD patients: A largely abandoned therapy. Nephrology Dialysis
Transplantation, 17(7), 1163.
Shoji, T., Tsubakihara, Y., Fujii, M., & Imai, E. (2004). Hemodialysis-associated
hypotension as an independent risk factor for two-year mortality in hemodialysis
patients. Kidney International , 66(3), 1212-1220. Retrieved on March 6, 2010
from:
http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=15327420
&site=ehost-live
Steuer, R. R., Germain, M. J., Leypoldt, J. K., & Cheung, A. K. (1998). Enhanced fluid
removal guided by blood volume monitoring during chronic hemodialysis.
Artificial Organs, 22(8), 627-632.

79

Szczech, L. A., & Lazar, I. L. (2004). Projecting the United States ESRD Population:
Issues regarding treatment of patients with ESRD. Kidney International , 66, S3S7.
Takeda, A., Toda, T., Fujii, T., Sasaki, S., & Matsui, N. (2006). Can predialysis
hypertension prevent intradialytic hypotension in hemodialysis patients?
Nephron.Clinical Practice, 103(4), c137-43. Retrieved on March 6, 2010 from:
http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=16636581
&site=ehost-live
Timmers, L., Thong, M., Dekker, F., Boeschoten, E., Heijmans, M., Rijken, M., et al.
(2008). Illness perceptions in dialysis patients and their association with quality of
life. Psychology and Health, 23(6), 679-690.
Tomson, C. R. V. (2001). Advising dialysis patients to restrict fluid intake without
restricting sodium intake is not based on evidence and is a waste of time.
Nephrology, Dialysis, Transplant ., 16(8), 1538-1542. doi:10.1093/ndt/16.8.1538
National Institute of Diabetes and Digestive and Kidney Diseases. (2010). United States
Renal Data System. 2010 Annual Report. Atlas of Chronic Kidney Disease and
End Stage Renal Disease in the United States. Retrieved from http://www.usrds
.org/atlas.htm
Vlaminck, H., Maes, B., Jacobs, A., Reyntjens, S., & Evers, G. (2001). The dialysis diet
and fluid non-adherence questionnaire: Validity testing of a self-report instrument
for clinical practice. Journal of Clinical Nursing, 10(5), 707.
Wang, T. J., & Vasan, R. S. (2005). Epidemiology of uncontrolled hypertension in the
United States. Circulation, 112(11), 1651.
Wasserstein, A. G. (2005). CORE CURRICULUM IN NEPHROLOGY. A merican
Journal of Kidney Diseases, 45(2), 422-428.
Welch, J. L. (2001). Hemodialysis patient beliefs by stage of fluid adherence. Research in
Nursing & Health, 24(2), 105-112.
Williams, A. F., Manias, E., & Walker, R. (2008). Adherence to multiple, prescribed
medications in diabetic kidney disease: A qualitative study of consumers’ and
health professionals’ perspectives. International Journal of Nursing Studies,
45(12), 1742-1756.
Wilson, J., Shah, T., & Nissenson, A. R. (2004). Role of sodium and volume in the
pathogenesis of hypertension in hemodialysis. Sem inars in Dialysis, 17(4), 260264. Retrieved on March 6, 2010 from:
http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=15250914
&site=ehost-live
Xue, J. L., Ma, J. Z., Louis, T. A., & Collins, A. J. (2001). Forecast of the number of
patients with end-stage renal disease in the United States to the year 2010.
Journal of the A merican Society of Nephrology, 12(12), 2753-2758.
Zoccali, C., Benedetto, F. A., Tripepi, G., & Mallamaci, F. (2004). Cardiac consequences
of hypertension in hemodialysis patients. Seminars in Dialysis, 17(4), 299-303.

80

Retrieved on March 6, 2010 from :
http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=15250922
&site=eho
Zoccali, C., Mallamaci, F., & Tripepi, G. (2000). Inflammation and atherosclerosis in
end-stage renal disease. Blood Purification, 21(1), 29-36.

81

